Annual Report 2021

of the Certified Prostate Cancer Centres

Audit year 2020 / Indicator year 2019

DKG
GERMAN CANCER SOCIETY
Certification

Content

General information

Quality indicators of the guidelines (LL QI):
In the table of contents and in the respective headings the indicators, which correspond to the quality indicators of the evidence-based guidelines are specifically identified. The quality indicators identified in this way are based on the strong recommendations of the guidelines and were derived from the guidelines groups of the guidelines programme oncology. Further information: www.leitlinienprogramm-onkologie.de
The quality indicators (QI's) refer to version 5.1 of the S3-LL for early detection, diagnosis and therapy of the various stages of prostate cancer.

Basic data indicator:
The definitions of **numerator**, **population (=denominator)** and **target value** are taken from the Indicator Sheet.
The **medians** for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators.
The values for the numerators, populations and rates of all Centres are given under range.
The Total Patients column shows the total of all patients treated according to the indicator and the corresponding quota.

Diagram:
The x-axis indicates the number of Centres, the y-axis gives the values in percent or number (e.g. primary cases). The target value is depicted as a horizontal green line. The median, which is also depicted as a green horizontal line, divides the entire group into two equal halves.

General information

Cohort development:
The cohort development in the years **2015, 2016, 2017, 2018** and **2019** is presented in a box plot diagram. This chart provides the distribution overview of each cohort's indicator year and direct comparison to the previous year.

Maximalwe = Maximum value
Antenna = Antenne
Minamalwert = Minimum value

Boxplot:
A box plot consists of a **box with median**, **whiskers** and **outliers**.50 percent of the Centres are within the box. The median divides the entire available cohort into two halves with an equal number of Centres. The whiskers and the box encompass a 90th percentile area/range. The extreme values are depicted here as dots.

Status of the certification system: Prostate Cancer Centres 2020

	31.12.2020	31.12.2019	31.12.2018	31.12.2017	31.12.2016	31.12.2015
Ongoing procedures	22	6	3	9	7	5
Certfied centres	131	127	122	112	103	97
Certified clinical sites	132	128	123	113	104	98

Considered locations

	31.12.2020	31.12.2019	31.12.2018	31.12.2017	31.12.2016	31.12.2015
Clinical sites included in the Annual Report	124	122	115	106	95	94
Equivalent to	93.9%	95.3%	93.5%	93.8%	91.3%	95.9%
Primary cases total*	30,528	29,344	27,160	23,677	20,643	18,684
Primary cases per centre (mean)*	246	241	236	223	217	199
Primary cases per centre (median)*	171	170	165	165	159	139

*The figures are based on the clinical sites listed in the Annual Report.

This Annual Report looks at the Prostate Cancer Centres certified in the Certification System of the German Cancer Society. The Indicator sheet which is part of the Catalogue of Requirements (Catalogue of Requirements Certification) is the basis for the diagrams.

The annual report includes 124 of the 132 certified centre locations. Excluded are 4 sites that were certified for the first time in 2020 (data mapping of complete calendar year not mandatory for first-time certifications), 2 sites for which the data sheet could not be generated completely via the OncoBox (first certification in 2019 and change of tumour documentation system) and 2 sites for which the verification of the data could not be completed on time for internal hospital reasons. A total of 31,811 primary cases of Pca were treated at 132 sites with available data sheets. www.oncomap.de provides an updated overview of all certified centres.

The indicators published here refer to the indicator year 2019. They are the basis for the audits conducted in 2020.

Tumour documentation systems used in Prostate Cancer Centres

Pie chart labels:

- Andere: 15 (12,10 %)
- CREDOS: 7 (5,65 %)
- Tudok (Tumorzentrum Regensburg): 4 (3,23 %)
- ORBIS-ODOK: 8 (6,45 %)
- Ondis: 10 (8,06 %)
- ONKOSTAR: 11 (8,87 %)
- c37.CancerCenter: 7 (5,65 %)
- ProDoS: 3 (2,42 %)
- ODSeasy / ODSeasy Net: 27 (21,77 %)
- GTDS: 32 (25,81 %)

Legende:	
Andere („others")	System used in ≤ 3 clinical sites

The information on the tumour documentation system was taken from the data sheet (Basic Data Sheet). It is not possible to specify more than one system. In many cases, support is provided by the cancer registries or there may be a direct link to the cancer registry via a specific tumour documentation system.

Basic data – Primary cases PCa

Total primary cases

	Total primary cases
Locally confined (T1/2, N0, M0), Low risk	5,041 (16.51%)
Locally confined (T1/2, N0, M0), Intermediate risk	11,913 (39.02%)
Locally confined (T1/2, N0, M0), High risk	8,520 (27.91%)
Locally advanced (T3/4, N0, M0)	1,577 (5.17%)
Advanced (N1, M0)	659 (2.16%)
Advanced (N0/1, M1)	1,814 (5.94%)
No clear classification [1]	1,004 (3.29%)
Total primary cases	30,528

1) Not assignable: Nx, Mx, random findings after radical cystoprostatectomy

Basic data

Non-interventional / interventional primary cases

	Non interventional[1]	Interventional	Total
Locally confined (T1/2, N0, M0), Low risk	1,741 (34.54%)	3,300 (65.46%)	5,041 (100%)
Locally confined (T1/2, N0, M0), Intermediate risk	714 (5.99%)	11.199 (94.01%)	11,913 (100%)
Locally confined (T1/2, N0, M0), High risk	234 (2.75%)	8.286 (97.25%)	8,520 (100%)
Locally advanced (T3/4, N0, M0)	14 (0.89%)	1.563 (99.11%)	1,577 (100%)
Advanced (N1, M0)	4 (0.61%)	655 (99.39%)	659 (100%)
Advanced (N0/1, M1)	13 (0.72%)	1.801 (99.28%)	1,814 (100%)
No clear classification [2]	96 (9.56%)	908 (90.44%)	1,004 (100%)
Total primary cases	2,816	27,712	30,528

1) Non-interventional: active surveillance or watchful waiting; requirement: histologically confirmed PCa
2) Not clear classification: Nx, Mx, random findings after radical cystoprostatectomy

Basic data

Non-interventional primary cases (locally confined) – Distribution of therapies

	Non-interventional[1]		Total
	Active-Surveillance[1]	Watchful Waiting[1]	
Locally confined (T1/2, N0, M0), Low risk	1,363 (78.29%)	378 (21.71%)	1,741 (100%)
Locally confined (T1/2, N0, M0), Intermediate risk	429 (60.08%)	285 (39.92%)	714 (100%)
Locally confined (T1/2, N0, M0), High risk	90 (38.46%)	144 (61.54%)	234 (100%)
Total primary cases (locally confined)	1,882	807	2,689

1)   Non-interventional: active surveillance or watchful waiting; requirement: histologically confirmed PCa

10

Basic data

Primary cases - Distribution of therapies

	Non-interventional (Active surveillance, Watchful waiting)	Interventional - local treatment of the prostate[1]	Interventional - exclusive systemic treatment	Interventional - other non-local treatment[2]	Total
Locally confined (T1/2, N0, M0), Low risk	1,741 (34.54%)	3,252 (64.51%)	10 (0.20%)	38 (0.75%)	5.041 (100%)
Locally confinded (T1/2, N0, M0), Intermediate risk	714 (5.99%)	11,037 (92.65%)	86 (0.72%)	76 (0.64%)	11,913 (100%)
Locally confinded (T1/2, N0, M0), High risk	234 (2.75%)	7,693 (90.29%)	397 (4.66%)	196 (2.30%)	8,520 (100%)
Locally advanced (T3/4, N0, M0)	14 (0.89%)	1,404 (89.03%)	106 (6.72%)	53 (3.36%)	1,577 (100%)
Advanced (N1, M0)	4 (0.61%)	507 (76.93%)	109 (16.54%)	39 (5.92%)	659 (100%)
Advanced (N0/1, M1)	13 (0.72%)	266 (14.66%)	1,118 (61.63%)	417 (22.99%)	1,814 (100%)
No clear classification [2]	96 (9.56%)	858 (85.46%)	35 (3.49%)	15 (1.49%)	1,004 (100%)
Total primary cases	2,816	25,017	1,861	834	30,528

1) Interventional - local treatment of the prostate: e.g. Radical Prostatectomy, Radical Cystoprostatectomy, Definitive Percutaneous Radiation, Brachytherapy,
2) Interventional - other non-local treatment: e.g. palliative radiation of bone metastases, best supportive care.
3) Not to be assigned: Nx, Mx, incidental findings after radical cystoprostatectomy.

Basic data

DKG
GERMAN CANCER SOCIETY
Certification

Interventional primary cases treated - Distribution of therapies

	RPE [3]	RCE [4] due to PCa	Incidental finding after RCE [4]	Definitive percutaneous radiotherappy	LDR brachytherapy	HDR brachytherapy	Other local therapy[1]	Total
				Interventional – local treatment of prostata				
Locally confined (T1/2, N0, M0) Low risk	2,576 (79.21%)	11 (0.34%)	0 (0.00%)	482 (14.82%)	117 (3.60%)	15 (0.46%)	51 (1.57%)	3,252 (100%)
Locally confinded (T1/2, N0, M0) Intermediate risk	8,732 (79.12%)	20 (0.18%)	0 (0.00%)	2,026 (18.36%)	71 (0.64)	72 (0.65%)	116 (1.05%)	11,037 (100%)
Locally confinded(T1/2, N0, M0) High risk	5,790 (75.26%)	24 (0.31%)	0 (0.00%)	1,767 (22.97%)	15 (0.19%)	85 (1.10%)	12 (0.16%)	7,693 (100%)
Locally advanced (T3/4, N0, M0)	996 (70.94%)	14 (1.00%)	0 (0.00%)	376 (26.78%)	0 (0.00%)	18 (1.28%)	0 (0.00%)	1,404 (100%)
Advanced (N1, M0)	310 (61.14%)	7 (1.38%)	0 (0.00%)	187 (36.88%)	1 (0.20%)	2 (0.39%)	0 (0.00%)	507 (100%)
Advanced (N0/1, M1)	140 (52.63%)	11 (4.14%)	0 (0.00%)	110 (41.35%)	0 (0.00%)	5 (1.88%)	0 (0.00%)	266 (100%)
No clear classfication [3]	106 (12.35%)	30 (3.50%)	659 (76.81%)	57 (6.64%)	2 (0.23%)	1 (0.12%)	3 (0.35%)	858 (100%)
Total primary cases	18,650	117	659	5,005	206	198	182	25,017

1) Other local therapy: e.g. HIFU,….

2) Not to be assigned: Nx, Mx, incidental findings after radical cystoprostatectomy

3) Radical prostatectomy

4) Radicals Zystoprostatectomies

Basic data

Newly diagnosed recurrence – distribution of therapies

Newly diagnosed remote metastasis – distribution of therapies

	Active-Surveillance	Watchful Waiting	RPE [1]	RZE [2] due to Pca	Incidential finding after RCE	Definitive percuaneous radiotherapy	LDR-Brachy-Therapy	HDR-Brachy-Therapy	other local Therapie [3]	Exclusive systemic therapy	Other therapy [4]	Total
Pat. with newly diagnosed recurrence	29 (0.88%)	42 (1.28%)	129 (3.94%)	18 (0.55%)	0 (0.00%)	1.299 (39.63%)	3 (0.09%)	31 (0.95%)	44 (1.34%)	300 (9.15%)	1.383 (42.19%)	3.278 (100%)
Pat. with newly diagnosed remote metastasis	6 (0.43%)	4 (0.29%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	333 (23.94%)	1.048 (75.34%)	1.391 (100%)

1) Other therapy: i.e. radiotherapy of bone metastases
2) Radical cystoprostatectomy
3) Other local therapies, i.e. HIFU, …
4) Other treatment: radiotherapy bone metastasis

Basic data – Primary case distribution in the indicator years 2015-2019

Distribution primary cases 2015-2019

1) No clear classification: Nx, Mx, coincidental diagnosis after radical cysto-proctectomy

Basic data – Primary case distribution in the indicator years 2015-2019

Distribution of interventional / non-interventional primary cases 2015-2019

■ 2015 ■ 2016 ■ 2017 ■ 2018 ■ 2019

Distribution non-interventional primary cases prostate cancer 2015-2019

Categories: Locally confined - Low risk, Locally confined - Intermediate risk, Locally confined - High risk, Locally advanced, Advance metastasi, No classification[1]

■ 2015 ■ 2016 ■ 2017 ■ 2018 ■ 2019

Distribution of interventional primary cases of prostate cancer 2015-2019

Categories: Locally confined - Low risk, Locally confined - Intermediate risk, Locally confined - High risk, Locally Advanced, Advanced/ metastasised, No classification[1]

■ 2015 ■ 2016 ■ 2017 ■ 2018 ■ 2019

1) No clear classification: Nx, Mx, coincidental diagnosis after radical cysto-proctectomy

1a. Number of primary cases of prostate carcinoma

Number

Median 171.00

Sollvorgabe ≥ 100

124 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients total**
Number	Primary cases	171	101 – 2,768	30,528
	Target value ≥ 100			

		2015	**2016**	**2017**	**2018**	**2019**
●	Max	2,416.00	2,250.00	2,626.00	2,668.00	2,768.00
⊤	95th percentile	405.80	468.25	454,60	463.70	451.50
	75th percentile	200.50	225.50	254.50	264.50	274.00
	Median	159.00	165.00	165.00	170.00	171.00
	25th percentile	122.50	131.00	134.50	136.25	143.75
	5th percentile	105.70	108.25	112.10	109.05	114.00
●	Min	94.00	98.00	89.00	102.00	101.00

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	124	100.00%

Comment:
As in the previous year, all centres reach the target value of 100 primary cases. Over the years, a slight increase in the median to now 171 primary cases can be seen. In total, 30,528 primary cases were treated in the centres included in the annual report in 2019, of which 28,651 were treated in Germany. This corresponds to an increase of 4.03% compared to the pre-indicator year.

1b1. Distribution of primary cases with locally confined prostate carcinoma and low risk

Number

124 clinical sites

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients total**
Number	Primary cases with locally confined PCa and low risk (PSA ≤ 10ng/ml and cT category ≤ 2a)	32	5 - 423	5,041
	No target value			

		2015	**2016**	**2017**	**2018**	**2019**
●	Max	462.00	415.00	446.00	439.00	423.00
	95th percentile	99.30	80.00	84.00	87.90	81.85
	75th percentile	45.50	43.50	44.00	45.00	44.50
	Median	29.00	30.50	31.00	28.50	32.00
	25th percentile	21.50	21.00	21.00	22.00	20.00
	5th percentile	11.70	11.25	10.40	12.00	11.00
●	Min	1.00	4.00	7.00	7.00	5.00

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	-----	-----

Comment
19.79% of primary cases with locally limited prostate carcinoma were assigned to low risk. This proportion is at the same level as in previous years (2018: 20.22%, 2017: 17.52%, 2016: 18.01%). In absolute numbers, the size of this patient group across all centres increased slightly by 2.7% to now 5,041 patients.

1b2. Distribution of primary cases with locally confined prostate carcinoma and intermediate risk

Number

Median 64.50

124 clinical sites

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Number	Primary cases with locally confined PCa and intermediate risk (PSA > 10-20 ng/ml or Gleason-Score 7 or cT 2b)	64.5	10 – 1,615	11,913
	No target value			

		2015	**2016**	**2017**	**2018**	**2019**
●	Max	1,212.00	1,146.00	1,459.00	1,581.00	1,615.00
	95th percentile	149.20	171.75	169.70	199.10	189.00
	75th percentile	77.50	78.75	87.50	90.75	96.25
	Median	51.00	49.00	54.00	60.00	64.50
	25th percentile	37.00	39.25	38.50	41.25	47.75
	5th percentile	21.70	27.25	23.70	31.00	26.15
●	Min	16.00	11.00	17.00	20.00	10.00

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	-----	-----

Comment

The proportion of intermediate-risk patients among primary cases with localised prostate cancer has remained roughly constant at 46.77% (2018: 46.91%). The absolute number of intermediate-risk patients across all centres in the annual report has increased slightly by 4.63%.

18

1b3. Distribution of primary cases with locally confined prostate carcinoma and high risk

DKG GERMAN CANCER SOCIETY
Certification

Number

124 clinical sites

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Number	Primary cases with locally confined PCa and high risk (PSA > 20 ng/ml or Gleason-Score ≥ 8 or cT2c)	50.5	15 - 660	8,520
	No target value			

		2015	2016	2017	2018	2019
●	Max	635.00	614.00	613.00	624.00	660.00
	95th percentile	128.20	110.75	134.50	133.35	147.20
	75th percentile	63.50	72.75	81.00	73.25	71.25
	Median	42.00	46.00	49.00	48.00	50.50
	25th percentile	31.00	33.00	35.00	35.00	38.00
	5th percentile	21.00	20.50	24.00	22.00	26.15
●	Min	16.00	9.00	12.00	14.00	15.00

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	-----	-----

Comment
About one third (33.35%) of the locally limited prostate carcinomas belonged to the high-risk group in the indicator year 2019. All three subgroups are thus roughly at the level of the previous year (2018: 32.87% at high risk). A slight increase in the number of cases (+6.79%) was also observed here.

2a. Presentation at the weekly pre-therapeutic tumour board – Urology

DKG GERMAN CANCER SOCIETY
Certification

Rate

Median 98.50

Sollvorgabe ≥ 95%

124 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	All patients presented in the pre-therapeutic tumour board	128.5*	39 – 2,648	23,528
Denominator	All patients who presented themselves to the health care providers (urology/ radiotherapy) (e.g. via referral) and have been diagnosed as primary cases in line with CoR 1.2.1 (without primary M1)	131,5*	40 – 2,691	24,412
Rate	Target value ≥ 95%	98.50%	49.11% - 100%	96.38% **

	2015	2016	2017	2018	2019
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	100%	100%	100%	100%	100%
Median	97.98%	98.19%	99.00%	98.76%	98.50%
25th percentile	95.95%	96.38%	95.63%	96.71%	96.07%
5th percentile	83.90%	90.42%	90.10%	92.42%	88.53%
Min	56.63%	74.66%	43.33%	83.05%	49.11%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	108	87.10%

Comment
The fulfilment of this indicator is approximately at the previous year's level. 16 centres failed to meet the target in 2019, which was attributed, among other things, to incidental findings in radical cystectomy, personnel changes or simply an omission. The 3 centres with rates below 55% referred to a change in presentation practice prior to certification or to software problems. Better results are expected from them for the following year.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

2b. Presentation at the weekly pre-therapeutic tumour board – Radiotherapy

DKG GERMAN CANCER SOCIETY
Certification

Rate

114 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	All patients presented in the pre-therapeutic tumour board	26.5*	1 - 132	3,425
Denominator	All patients who presented themselves to the health care providers I (urology/ radiotherapy) (e.g. via referral) and have been diagnosed as primary cases in line with EB 1.2.1 (without primary M1)	27.5*	1 - 132	3,497
Rate	Target value ≥ 95%	100%	50.00% - 100%	97.94%**

	2015	2016	2017	2018	2019
Max	100%	100%	100%	100%	100%
95th percentile	100%	100%	100%	100%	100%
75th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25th percentile	96.93%	98.00%	98.42%	97.69%	100%
5th percentile	60.64%	84.83%	83.00%	85.98%	88.81%
Min	0.00%	60.00%	40.00%	50.00%	50.00%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
114	91.94%	106	92.98%

Comment
The indicator for radiotherapy presentation continues to develop positively. Only 8 centres (previous year 9) still fail to meet the target. The reasons range from a post-therapeutic presentation only to staff shortages and omissions. In many cases, measures such as quality circles and staff sensitisation were agreed upon in the audits. Of the two centres with scores around 50%, one was certified for the first time in the 2019 audit year. The other centre is an outlier compared to previous years (no external presentation at the time of the TB decision).

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

21

3a. Presentation in the monthly tumour board – Primary cases post-operative

Rate

124 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2019		
		Median	Range	Patients total
Numerator	All patients presented in the post-therapeutic tumour board	28*	8 - 812	6,103
Denominator	Primary cases > pT3a and/or R1 and/or pN+	29*	8 - 866	6,272
Rate	Target value = 100%	100%	41.33% - 100%	97.31%**

		2015	2016	2017	2018	2019
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	100%	100%	100%	100%	100%
	Median	100%	100%	100%	100%	100%
	25th percentile	100%	100%	100%	100%	100%
	5th percentile	92.35%	95.09%	95.15%	91.35%	90.35%
●	Min	64.21%	73.18%	5.26%	80.65%	41.33%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	99	79.84%

Comment

99 centres presented all patients of the denominator postoperatively in the TB. 25 centres failed to meet this target and attributed this to the failure to present (usually individual) patients, lack of process knowledge due to staff changes, patients who died postoperatively and problems with the hospital software. The centre with a rate of 41.33% identified the lack of checks on TB registrations as the cause and initiated improvements in the registration process.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

3b. Presentation in the monthly tumour board – Primary cases primary M1 pre-therapeutic

DKG
GERMAN CANCER SOCIETY
Certification

Sollvorgabe = target value

124 clinical sites

	Definition of indicator	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Patients of the denominator who were presented in the tumour board	13*	1 - 42	1,821
Denominator	Primary cases with primary M1	13.5*	1 - 42	1,852
Rate	Target value = 100%	100%	72.73% - 100%	98.33%**

	2015	2016	2017	2018	2019
Max	-----	100%	100%	100%	100%
95th percentile	-----	100%	100%	100%	100%
75th percentile	-----	100%	100%	100%	100%
Median	-----	100%	100%	100%	100%
25th percentile	-----	100%	100%	100%	100%
5th percentile	-----	89.40%	90.84%	87.50%	87.61%
Min	-----	66.67%	31.58%	71.43%	72.73%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	106	85.48%

Comment
The pre-therapeutic presentation of primary M1 patients in the tumour board remains at a high level. 18 centres do not succeed in presenting each of these patients, which was mostly due to organisational problems (patients assigned from another hospital, personnel changes, omissions, change of tumour documentation system). Measures for improvement therefore mainly concerned the regulation of responsibilities, training, reviews and SOP.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

3c. Presentation in the monthly tumour board – Recurrence/ metastases pre-therapeutic

DKG
GERMAN CANCER SOCIETY
Certification

Rate

Median 100,00%
Sollvorgabe = 100%

124 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Patients of the denominator who were presented in the pre-therapeutic tumour board	26*	0 - 168	4,436
Denominator	All patients with primary diagnosis, recurrence and/or distant metastases	27.5*	1 - 168	4,669
Rate	Target = 100%	100%	0.00% - 100%	95.01%**

		2015	**2016**	**2017**	**2018**	**2019**
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	100%	100%	100%	100%	100%
	Median	100%	100%	100%	100%	100%
	25th percentile	89.38%	85.00%	90.11%	93.33%	96.58%
	5th percentile	43.09%	43.88%	53.61%	63.30%	71.82%
●	Min	17.39%	17.91%	17.65%	25.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	86	69.35%

Comment
Over the years, there has been a clear improvement in meeting this indicator. 38 centres (previous year: 44) did not present all patients of the denominator. Often, the presentation of individual patients was missed, they were only presented post-therapeutically or after the initiation of therapy by general practitioners/cooperation partners, a presentation was waived. The auditors made 4 recommendations and called for organisational improvements. The centre with a rate of 0% (with 6 patients in the denominator) participated in data collection for the first time in 2019. It was encouraged to conduct internal reviews.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

4. Active Surveillance (AS)

Rate

124 clinical sites

Begründungspflicht = mandatory statement for reason

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Primary cases under AS	9*	0 - 51	1,363
Denominator	Primary cases with locally confined PCa and low risk(PSA ≤ 10ng/ml and Gleason-Score 6 and cT category ≤ 2a)	32*	5 - 423	5,041
Rate	Mandatory statement of reasons*** <0.01% and >90%	31.42%	0.00% - 88.89%	27.04%**

		2015	**2016**	**2017**	**2018**	**2019**
●	Max	70.00%	75.00%	83.33%	87.50%	88.89%
	95th percentile	57.78%	65.65%	68.27%	70.12%	69.52%
	75th percentile	29.29%	45.03%	48.71%	42.15%	47.91%
	Median	21.05%	25.00%	27.27%	27.53%	31.42%
	25th percentile	10.76%	10.98%	14.12%	13.43%	11.35%
	5th percentile	2.43%	0.94%	1.02%	1.19%	0.95%
●	Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	118	95.16%

Comment
The trend towards increasing rates of AS patients continues in the indicator year 2019. At the 6 centres outside the plausibility corridor, no patient was under active surveillance. This was mostly due to the fact that the AS was carried out by a general practitioner or the outpatient clinic did not have a KV authorisation, which is why the patients were not counted in the indicator. In some cases, the patients refused the AS and insisted on therapy.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

5. Percutaneous radiotherapy with hormone ablation therapy for locally confined PCa with high risk (GL QI 4)

DKG GERMAN CANCER SOCIETY
Certification

122 clinical sites

Begründungspflicht = mandatory statement for reason

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Primary cases with additional neo- and/or adjuvant hormone ablation therapy	10*	0 - 39	1,319
Denominator	Primary cases with prostate carcinoma T1-2 N0 M0 with high risk (PSA >20ng/ml or Gleason-Score ≥ 8 or cT category 2c) and percutaneous radiotherapy	14*	1 - 56	1,767
Rate	Mandatory statement of reasons*** <90%	80.00%	0.00% - 100%	74.65%**

		2015	**2016**	**2017**	**2018**	**2019**
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	91.26%	100%	95.24%	100%	94.27%
	Median	75.00%	84.52%	80.00%	86.34%	80.00%
	25th percentile	60.05%	61.63%	57.14%	60.00%	62.62%
	5th percentile	26.25%	33.54%	28.00%	26.59%	24.69%
●	Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
122	98.39%	46	37.70%

Comment
The wide dispersion of this guideline indicator remains. While 2 centres have no patients in the denominator, 76 centres are below a rate of 90%. In the vast majority of cases, patient rejection and/or advanced age or comorbidities were the reasons for not initiating additional hormone ablation therapy. In some cases, however, this was recommended but not initiated by the general practitioners or no information was available. Here, the applicable recommendations of the guideline were partly communicated.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

6. Psycho-oncologic care

DKG
GERMAN CANCER SOCIETY
Certification

Rate

124 clinical sites

Begründungspflicht = mandatory statement for reason

	Definition of indicator	All clinical sites 2019		
		Range	**Median**	**Patients Total**
Numerator	Patients who received psycho-oncologic care (duration of consultation ≥ 25 min)	43*	2 - 716	7,430
Denominator	Primary cases (= indicator 1a) and patients with first manifestation of local recurrence and/or metastases (= indicator 3c)	214*	106 – 2,928	35,197
Rate	Mandatory statement of reasons*** <4% and >80%	19.24 %	0.67% - 77.10%	21.11%**

		2015	**2016**	**2017**	**2018**	**2019**
●	Max	72.50%	86,71%	93.94%	84.73%	77.10%
	95th percentile	56.11%	56.79%	60.47%	55.09%	52.15%
	75th percentile	35.73%	39.48%	36.82%	37.00%	35.27%
	Median	19.25%	21.62%	17.51%	21.01%	19.24%
	25th percentile	8.65%	7.66%	8.39%	9.17%	8.94%
	5th percentile	2.06%	1.94%	1.58%	1.79%	2.51%
●	Min	1.08%	1.12%	0.70%	0.52%	0.67%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	112	90.32%

Comment
The psycho-oncological counselling rate remained approximately at the same level as in previous years, with a large scattering of individual values. The 12 centres with counselling rates below 4 % stated that the need for counselling of prostate cancer patients (often also due to the comparatively good prognosis) was lower overall than for other tumour entities. Individual centres announced that they would intensify their screening efforts.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausability corridor, centres have to give an explanation.

7. Social service counselling

DKG
GERMAN CANCER SOCIETY
Certification

Rate

Median 51,56%
Begründungspflicht < 50%

124 clinical sites

Begründungspflicht = mandatory statement for reason

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Patients who received social service counselling	101*	0 – 1,755	18,043
Denominator	Primary cases (= indicator 1a) and patients with first manifestation of local recurrence and/or metastases (= indicator 3c)	214*	106 – 2,928	35,197
Rate	Mandatory statement of reasons*** <50%	51.56%	0.00% - 91.22%	51.26%**

		2015	**2016**	**2017**	**2018**	**2019**
●	Max	99.10%	94,90%	89.87%	88.22%	91.22%
	95th percentile	78.13%	78.01%	75.22%	74.96%	77.00%
	75th percentile	60.64%	61.76%	60.42%	60.25%	60.45%
	Median	51.23%	51.40%	50.75%	51.04%	51.56%
	25th percentile	39.76%	40.29%	35.94%	39.65%	39.66%
	5th percentile	5.96%	5.77%	5.36%	3.43%	4.65%
●	Min	0.00%	0.00%	0.40%	0.39%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	73	58.87%

Comment
The social counselling rate is also at the same level as in previous years. 51 centres had to justify their rate of less than 50% for the audit. They mainly referred to low demand, especially from non-operated patients. In addition, many outpatients were not offered social counselling for billing and organisational reasons. In the audits, there was a push for consistent screening and consistent provision. An exception are the centres in Switzerland and Luxembourg, for which other responsibilities/benefit entitlements apply.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

8. Clinical trial participation

Rate

Median 39.09%

Sollvorgabe ≥ 5%

122 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Patients included in a clinical trial subject to an ethics vote	65.5*	0 - 1700	16,349
Denominator	Primary cases (= indicator 1a)	171*	101 – 2,768	30,528
Rate	Target value ≥5%	39.09%	0.00% - 345.43%	53.55%**

		2015	2016	2017	2018	2019
●	Max	94.58%	84.69%	190.94%	449.77%	345.43%
	95th percentile	50.22%	58.46%	65.54%	82.22%	105.88%
	75th percentile	17.80%	18.25%	38.07%	43.35%	52.99%
	Median	6.23%	8.12%	17.25%	26.39%	39.09%
	25th percentile	0.81%	2.10%	7.24%	13.36%	23.24%
	5th percentile	0.00%	0.00%	0.62%	5.46%	7.41%
●	Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100,00%	118	95,16%

Comment

The median study rate continued to rise, which had already been expected in the previous year due to the participation of more centres in the PCO study. 6 centres were able to enrol fewer patients than 5% of the primary case load in studies. The reason for this was the delayed inclusion of patients, which was planned in 2019 but could not be realised until 2020, as well as problems with the documentation regarding the study quota by the referring physicians. In 2 cases, the experts gave advice on how to improve the study quota.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

29

9. Number of prostatectomies – Centre

	Definition of indicator	All clinical sites 2019		
		Median	Range	Patients Total
Number	Total number of radical prostatectomies/ cystoprostatectomies (see basic data)	84	27 – 2,642	19,573
	Target value ≥ 50			

Sollvorgabe = target value

|		2015	2016	2017	2018	2019
●	Max	2639,00	2084,00	2387.00	2498.00	2642.00
	95th percentile	344.70	374.25	372.30	368.50	372.90
	75th percentile	122.50	140.00	151.00	156.00	166.50
	Median	79.00	73.50	76.00	81.00	84.00
	25th percentile	58.00	56.25	56.00	59.50	60.75
	5th percentile	37.10	34.50	34.00	42.00	40.75
●	Min	31.00	17.00	26.00	26.00	27.00

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	112	90.32%

Comment
The median number of prostatectomies has risen to 84. Only 12 centres (previous year: 16) fall short of the target of at least 50. The hospitals concerned reported staff shortages, competitive situations with neighbouring hospitals, often also in connection with the availability of surgical robots. They reacted to this by hiring new staff, optimising referral management and purchasing surgical robots. In the certified PZs, 18,617 (64%) of the 29,304 RPEs were performed in Germany1.
1© Federal Statistical Office (Destatis), Wiesbaden, 2021

30

10. Record of R1 resections for pT2 c/pN0 or Nx M0

124 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Operations with R1 status for primary cases with pT2 c/pN0 or Nx M0	5*	0 - 138	992
Denominator	Operations on primary cases with pT2 c/pN0 or Nx M0	46.5*	1 – 1,521	10,006
Rate	Target value ≤ 15%	9.54%	0.00% - 29.27%	9.91%**

|		2015	2016	2017	2018	2019
●	Max	41.54%	54.55%	50.00%	45.00%	29.27%
	95th percentile	19.05%	20.57%	25.00%	20.17%	19.97%
	75th percentile	12.85%	12.50%	12.50%	11.94%	13.57%
	Median	7.89%	7.95%	8.97%	8.66%	9.54%
	25th percentile	4.87%	4.31%	5.56%	5.18%	5.37%
	5th percentile	0.00%	0.00%	0.00%	0.00%	0.00%
●	Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	102	82.26%

Comment
Due to the increase of the target from max. 10 to max. 15 %, 22 centres (previous year: 47) now miss this limit. In many R1 patients, the intraoperative frozen section was tumour-free. In addition, some centres referred to the nerve-preserving surgical technique, generally difficult surgical conditions (e.g. due to local adhesions) or frozen incisions that were not performed. The technical experts made references in 2 cases.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

11. Definitive radiotherapy

Rate

124 clinical sites

Begründungspflicht = mandatory statement for reason

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Primary cases of the denominator with definitive radio-therapy	41*	2 - 132	5,005
Denominator	Primary cases (= indicator 1a)	171*	101 – 2,768	30,528
Rate	Mandatory statement of reasons*** <10% and >90%	18.75%	0.13% - 52.45%	16.39%**

		2015	**2016**	**2017**	**2018**	**2019**
●	Max	48.33%	45.81%	41.67%	52.20%	52.45%
	95th percentile	35.77%	38.91%	38.81%	39.02%	42.23%
	75th percentile	24.85%	26.24%	26.44%	28.33%	30.09%
	Median	16.95%	16.81%	18.39%	18.11%	18.75%
	25th percentile	10.80%	11.89%	11.42%	12.42%	11.16%
	5th percentile	2.70%	2.86%	3.97%	4.88%	2.81%
●	Min	0.48%	0.23%	0.41%	0.06%	0.13%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	97	78.23%

Comment
The proportion of primary cases with definitive radiotherapy increases slightly over the years. 27 centres had to explain rates below 10%: In most cases, the patient's wish for another therapy option was the reason for the low rate of radiotherapy. This is especially true for centres with high expertise in surgical therapy. In addition, many patients wanted radiotherapy close to home.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

32

12. Permanent seed implantation - D 90 > 130 Gy

Rate

Sollvorgabe = target value

22 clinical sites

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Primary cases for whom D90 > 130 Gy was achieved	7.5*	1 - 31	202
Denominator	Primary cases with LDR mono-therapy	7.5*	1 - 39	213
Rate	Target value ≥ 90%	100%	79.49% - 100%	94.84%**

	2015	2016	2017	2018	2019
Max	-----	-----	-----	-----	100%
95th percentile	-----	-----	-----	-----	100%
75th percentile	-----	-----	-----	-----	100%
Median	-----	-----	-----	-----	100%
25th percentile	-----	-----	-----	-----	100%
5th percentile	-----	-----	-----	-----	93.75%
Min	-----	-----	-----	-----	79.49%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
22	17.74%	21	95.45%

Comment
Due to the change in the denominator (previously: primary cases with permanent seed implantation), no comparison with previous years is possible. Only 1 centre failed to meet the target of at least 90% in the indicator year 2019: Here, some patients received LDR brachytherapy according to the ASCENDE RT protocol (dose: 115 Gy).

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

13. HDR brachytherapy

124 clinical sites

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Primary cases with HDR brachytherapy	0*	0 - 23	198
Denominator	Primary cases (= indicator 1a)	171*	101 – 2,768	30,528
Rate	No target value	0.00%	0.00% - 15.97%	0.65%**

	2015	**2016**	**2017**	**2018**	**2019**
Max	21.30%	20,98%	16.67%	14.57%	15.97%
95th percentile	8.27%	5.07%	4.20%	6.52%	5.30%
75th percentile	0.00%	0.00%	0.00%	0.00%	0.00%
Median	0.00%	0.00%	0.00%	0.00%	0.00%
25th percentile	0.00%	0.00%	0.00%	0.00%	0.00%
5th percentile	0.00%	0.00%	0.00%	0.00%	0.00%
Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	-----	-----

Comment
As in the two previous years, only 22 centres performed HDR brachytherapy at all, 19 of them with a share of less than 10%. Overall, the share of this therapy is at the same level as in previous years.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

14. Diagnostic report – Punch biopsy (GL QI 1)

DKG
GERMAN CANCER SOCIETY
Certification

Rate

124 clinical sites

Begründungspflicht = mandatory statement for reason

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Primary cases with complete diagnostic report	132*	38 – 1.460	21,536
Denominator	Primary cases with prostate carcinoma and vacuum biopsy	146*	43 – 2.744	26.131
Rate	Mandatory statement of reasons*** <10%	94.62%	18.73% - 100%	82.42%**

		2015	2016	2017	2018	2019
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	97.46%	95.32%	97.86%	98.06%	99.56%
	Median	88.75%	84.09%	88.16%	92.95%	94.62%
	25th percentile	56.69%	59.04%	70.42%	80.04%	84.92%
	5th percentile	12.96%	30.11%	45.74%	48.10%	55.83%
●	Min	0.00%	13.64%	3.60%	30.04%	18.73%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	124	100.00%

Comment
The positive development of the previous years continues in the indicator year 2019; none of the centres in the annual report falls below the quota for the obligation to provide justification of 10%. 79 centres were able to submit complete reports of findings in more than 90% of primary cases with punch biopsy, 28 (previous year: 17) even in 100%.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

15. Diagnostic report – Lymph nodes (GL QI 2)

Rate

124 clinical sites

Begründungspflicht = mandatory statement for reason

	Definition of indicator	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Primary cases with diagnostic reports stating: • pN category • number of affected lymph nodes in relation to resected lymph nodes	80.5*	15 – 2,355	17,495
Denominator	Primary cases with prostate carcinoma and lymphadenectomy	82.5*	16 – 2,357	17,687
Rate	Mandatory statement of rearsons*** <10%	100%	68.18% - 100%	98.91%**

		2015	2016	2017	2018	2019
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	100%	100%	100%	100%	100%
	Median	100%	100%	100%	100%	100%
	25th percentile	97.61%	98.32%	97.89%	98.17%	98.50%
	5th percentile	81.93%	92.78%	89.03%	88.17%	91.79%
●	Min	14.68%	51.24%	27.14%	32.61%	68.18%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
124	100.00%	124	100.00%

Comment
The development of the complete diagnostic report of findings for primary cases with lymphadenectomies is comparably positive as for indicator 14. Here, too, none of the centres falls below the 10% limit for the obligation to provide justification. 119 centres achieved at least 90% complete reports of findings, 79 (previous year: 75) even 100%.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

16. Begin salvage-radiotherapy for recurrent prostate cancer (GL QI 7)

Rate

Sollvorgabe = target value

118 clinical sites

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Patients with beginning SRT and PSA <0.5 ng/ml	7.5*	0 - 55	1,204
Denominator	Patients after RPE and PSA recurrence and SRT	9.5*	1 - 68	1,594
Rate	Target Value ≥ 70%	80.00%	0.00% - 100%	75.53%**

		2015	2016	2017	2018	2019
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	85.71%	94.92%	100%	100%	98.08%
	Median	69.57%	77.26%	80.00%	78.16%	80.00%
	25th percentile	46.06%	66.67%	71.83%	67.50%	67.28%
	5th percentile	25.36%	39.09%	36.85%	37.75%	39.63%
●	Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
118	95.16%	87	73.73%

Comment
Compliance with this guideline QI remains at the level of previous years. The 32 centres that started SRT in less than 70% of cases with a PSA<0.5 ng/ml stated in almost all cases that the patients were already assigned with a PSA value > 0.5. In individual cases, patients also presented themselves too late for follow-up or initially refused radiotherapy. Many centres exchanged information with the referring physicians and organised quality circles on this topic.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

18. Postoperative complications after radical prostatectomy (GL QI 9)

Rate

Begründungspflicht > 30%

Median 4,55%

25   50   75   100

123 clinical sites

Begründungspflicht = mandatory statement for reason

	Definition of indicator	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Primary cases with complications Clavien-Dindo grade III or IV within the first 6 months after RPE	4*	0 - 147	883
Denominator	Primary cases with PCa T1-2 N0 M0 and RPE (from the previous indicator year)	69*	22 – 2,463	15,820
Rate	Mandatory statement of reasons*** >30%	4.55%	0.00% - 28.57%	5.58%**

	2015	2016	2017	2018	2019
Max	25.00%	27.78%	28.30%	50.00%	28.57%
95th percentile	20.37%	18.09%	18.03%	19.70%	18.54%
75th percentile	12.53%	10.34%	9.73%	9.92%	8.70%
Median	6.47%	4.98%	4.55%	5.26%	4.55%
25th percentile	0.00%	0.00%	1.87%	1.29%	1.81%
5th percentile	0.00%	0.00%	0.00%	0.00%	0.00%
Min	0.00%	0.00%	0.00%	0.00%	0.00%

| Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
123	99.19%	123	100.00%

Comment
All centres report postoperative complications grade III/IV after Clavien-Dindo in less than 30% of the cases listed in the denominator. In the previous year, 1 centre was still conspicuous in this regard. 22 centres had no postoperative complications according to the numerator definition.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

19. Complexions after radiotherapy (GL QI 10)

19. Complications after radiotherapy (GL QI 10)

Sollvorgabe = target value

123 clinical sites

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Primary cases with complications CTCAE grade III or IV within the first 6 months after radiotherapy	0*	0 - 3	29
Denominator	Primary cases with PCa T1-2 N0 M0 and definitive ratiotherapy (from the previous indicator year)	43*	1 - 162	5,484
Rate	Target value ≤ 5%	0.00%	0.00% - 16.67%	0.53%**

		2015	2016	2017	2018	2019
●	Max	-----	-----	-----	5.26%	16.67%
	95th percentile	-----	-----	-----	3.82%	3.55%
	75th percentile	-----	-----	-----	0.00%	0.00%
	Median	-----	-----	-----	0.00%	0.00%
	25th percentile	-----	-----	-----	0.00%	0.00%
	5th percentile	-----	-----	-----	0.00%	0.00%
●	Min	-----	-----	-----	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
123	99.19%	122	99.19%

Comment
As in the previous year, 1 centre missed the target, although this was not the same centre. The rate of 16.67% was due to a single patient out of 6. Here, a grade III adverse effect (diarrhoea) was observed, which, however, did not require any further measures.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

39

20. Dental examination prior to commencement of bisphosphonate or denosumab Therapy (GL QI 8)

DKG
GERMAN CANCER SOCIETY
Certification

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Primary cases with a recommended dental examination prior to commencement of bisphosphonate or denosumab therapy	2*	0 - 81	4,25
Denominator	All primary cases with bisphosphonate or denosumab therapy	3*	1 - 83	524
Rate	No taget value	100%	0.00% - 100%	81.11%**

		2015	2016	2017	2018	2019
	Max	-----	-----	100%	100%	100%
	95. Perzentil	-----	-----	100%	100%	100%
	75. Perzentil	-----	-----	100%	100%	100%
	Median	-----	-----	30,00%	100%	100%
	25. Perzentil	-----	-----	1.53%	50.00%	50.00%
	5. Perzentil	-----	-----	0.31%	0.00%	0.00%
	Min	-----	-----	0.00%	0.00%	0.00%

| Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
82	66.13%	-----	-----

Comment
So far, there is no target for this guideline QI. The rate of recommendations for dental examinations prior to bisphosphonate or denosumab therapy is at the previous year's level. 42 centres had no patients in the denominator. In addition, many centres stated that bone-protective therapy is predominantly performed in the office-based setting. The denominator of the indicator will be adjusted for the following year (= patients instead of primary cases).

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

21. No hormone ablation therapy for locally progressed PCa with radical RPE (GL QI 5)

DKG
GERMAN CANCER SOCIETY
Certification

Rate

123 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patients Total**
Numerator	Primary cases with adjuvant hormone ablation therapy	0*	0 - 10	103
Denominator	Primary cases with PCa T3-4 N0 M0 and RPE	23*	3 - 748	4,736
Rate	Mandatory statement of reasons < 0.1%	0.00%	0.00% - 50.00%	2.17%**

		2015	2016	2017	2018	2019
●	Max	-----	-----	-----	-----	50.00%
	95th percentile	-----	-----	-----	-----	13.83%
	75th percentile	-----	-----	-----	-----	1.77%
	Median	-----	-----	-----	-----	0.00%
	25th percentile	-----	-----	-----	-----	0.00%
	5th percentile	-----	-----	-----	-----	0.00%
●	Min	-----	-----	-----	-----	0.00%

| Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
123	99.19%	88	71.54%

Comment
This guideline QI was compulsory for the first time in the 2019 indicator year. In the previous year, this was still voluntary and the denominator did not only refer to pT3-4. The 35 centres that performed adjuvant hormone-ablative therapy for locally advanced PCa and RPE justified this with individual decisions (patient wishes, high risk of progression/recurrence, high risk/R1 tumours, metastases after surgery). In some cases, external urologists had also initiated hormone ablative therapy. In the audits, the importance of the recommendation was pointed out in many cases, and in a few cases remarks was given.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

41

22. No hormonabl. therapy for locally confined PCa with low risk and percutant radiotherapy (GL QI 6)

DKG
GERMAN CANCER SOCIETY
Certification

Rate

Sollvorgabe < 0.1%

0,1%

Median 0,00%

0

25   50   75   100

107 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2019		
		Median	**Range**	**Patienten Gesamt**
Numerator	Primary cases with hormone ablation therapy	0*	0 - 0	0
Denominator	Primary cases with low risk prostate cancer T1-2 N0 M0 (PSA ≤ 10ng/ml and Gleason score 6 and cT category ≤ 2a) and percutaneous radiotherapy	3*	1 - 20	482
Rate	Taget value <0.1%	0%	0% - 0%	0.00%**

0,5%

2018   2019

		2015	2016	2017	2018	2019
●	Max	-----	-----	-----	0.00%	0.00%
	95th percentile	-----	-----	-----	0.00%	0.00%
	75th percentile	-----	-----	-----	0.00%	0.00%
	Median	-----	-----	-----	0.00%	0.00%
	25th percentile	-----	-----	-----	0.00%	0.00%
	5th percentile	-----	-----	-----	0.00%	0.00%
●	Min	-----	-----	-----	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
107	86.29%	107	100.00%

Comment
This guideline QI was also collected for the first time on a mandatory basis in the prostate cancer centres. As in the previous year, in not a single case was hormone ablative therapy performed on a patient of the denominator. This shows a complete implementation of the QI in the certified centres.

*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

WISSEN AUS ERSTER HAND
(FIRST-HAND KNOWLEDGE)

Find out more on www.krebsgesellschaft.de

Authors
German Cancer Society (DKG)
Certification Committee Prostate Cancer Centres
Martin Burchardt, Sprecher Zertifizierungskommission
Jan Fichtner, Sprecher Zertifizierungskommission
Simone Wesselmann, Deutsche Krebsgesellschaft e.V.
Johannes Rückher, Deutsche Krebsgesellschaft e.V.
Ellen Griesshammer, Deutsche Krebsgesellschaft e.V.
Verena Jörg, OnkoZert
Florina Dudu, OnkoZert

9 783948 226503